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Although environmental exposure to lead in
the United States has been reduced substan-
tially since the 1970s (1), bone stores of lead
accrued from environmental exposures and
found in most of the general population
have recently been linked to the develop-
ment of hypertension (2,3), cognitive decre-
ments (4,5), and adverse reproductive
outcomes (6). In adults, about 95% of the
total body burden of lead is stored in the
skeleton (7). Lead enters bone at the time of
mineral deposition and leaves bone at the
time of bone resorption. Therefore, factors
affecting bone turnover, such as pregnancy
(8–10), lactation (9), and menopause and
osteoporosis (11), can be expected to be
associated with increased mobilization of
lead from the skeleton. 
Cross-sectional studies have shown that
bone lead concentration increases with age
(12,13). However, in longitudinal analyses
of 70 participants in the Normative Aging
Study (NAS) (14), bone lead levels (particu-
larly those in the patella, a trabecular bone)
decreased over a 3-year follow-up interval.
This finding is not surprising in light of
recent declines in population blood lead lev-
els (1). Given that an increase in bone
resorption is a characteristic of aging in both
men and women, resorptive losses may also
contribute to longitudinal declines in bone
lead, particularly in older populations.
Aging-associated release of bone lead into
the circulation is, in fact, a potentially
important source of soft-tissue lead exposure
and toxicity (11). Indeed, in U.S. population
surveys, older adults have among the highest
blood lead levels, second only to the peak
observed in young children (1).
Plasma lead measurement provides criti-
cal information on the bioavailable fraction
of whole-blood lead (15–17) but is difﬁcult
to perform accurately because levels are
extremely low and may be affected by conta-
mination from hemolysis, sampling, and lab-
oratory handling (18–20). An alternative is
the measurement of urinary lead, which
originates from plasma lead filtered at the
glomerular level; thus, urinary lead levels
adjusted for glomerular filtration rate serve
as a marker of plasma lead. 
To assess the influence of bone resorp-
tion on lead mobilization from bone, partic-
ularly in studies in which bone lead levels are
being assessed as potential predictors of toxi-
city, biochemical markers that provide an
index of increased bone resorption are
needed. Urine cross-linked N-telopeptides of
type I collagen (NTx) are derived speciﬁcally
from bone collagen degradation and are con-
sidered a sensitive and specific marker of
bone resorption (21–23). In this study, we
assessed the influence of bone resorption
(estimated by 24-hr urinary NTx) on the
relationships of bone lead and blood lead
with urinary lead in a group of 333 middle-
aged and elderly men. The independent con-
tribution of bone lead to urinary lead has
been reported previously (24).
Materials and Methods
Study population. This investigation took
advantage of an ongoing longitudinal cohort
study of aging, the NAS, established in 1961
(25). The study cohort initially consisted of
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Articles
Bone stores of lead accrued from environmental exposures and found in most of the general pop-
ulation have recently been linked to the development of hypertension, cognitive decrements, and
adverse reproductive outcomes. The skeleton is the major endogenous source of lead in circulat-
ing blood, particularly under conditions of accelerated bone turnover and mineral loss, such as
during pregnancy and in postmenopausal osteoporosis. We studied the inﬂuence of bone resorp-
tion rate on the release of lead from bone in 333 men, predominantly white, middle-aged and
elderly (mostly retired) from the Boston area. We evaluated bone resorption by measuring cross-
linked N-telopeptides of type I collagen (NTx) in 24-hr urine samples with an enzyme-linked
immunosorbent assay. We used K-X-ray ﬂuorescence to measure lead content in cortical (tibia)
and trabecular (patella) bone; we used graphite furnace atomic absorption spectroscopy and
inductively coupled plasma mass spectroscopy to measure lead in blood and urine, respectively.
After adjustment for age and creatinine clearance, the positive relation of patella lead to urinary
lead was stronger among subjects in the upper two NTx tertiles (β for patella lead ≥ 0.015) than
in the lowest NTx tertile (β for patella lead = 0.008; overall p-value for interactions = 0.06). In
contrast, we found no statistically signiﬁcant inﬂuence of NTx tertile on the relationship of blood
lead to urinary lead. As expected, the magnitude of the relationship of bone lead to urinary lead
diminished after adjustment for blood lead. Nevertheless, the pattern of the relationships of bone
lead to urinary lead across NTx tertiles remained unchanged. Furthermore, after adjustment for
age, the relation of patella lead to blood lead was signiﬁcantly stronger in the upper two NTx ter-
tiles (β for patella lead ≥ 0.125) than in the lowest NTx tertile (β for patella lead = 0.072). The
results provide evidence that bone resorption inﬂuences the release of bone lead stores (particu-
larly patella lead) into the circulation. Key words: blood, bone, environmental exposure, K-X-ray
ﬂuorescence, lead, N-telopeptides, urine. Environ Health Perspect 109:995–999 (2001). [Online
________]
http://ehpnet1.niehs.nih.gov/docs/2001/109p995-999tsiah/abstract.htmlArticles • Tsaih et al.
996 VOLUME 109 | NUMBER 10 | October 2001 • Environmental Health Perspectives
2,280 predominantly white men from the
Greater Boston, Massachusetts, area. The
men were 21–80 years of age upon enroll-
ment. All participants were free of known
chronic medical conditions at the time of
enrollment; participants were excluded if
they had any history of hypertension, cancer,
recurrent asthma, sinusitis, bronchitis, dia-
betes, gout, or peptic ulcer. Since their
enrollment in 1961–1968, participants have
been reevaluated at 3- to 5-year intervals by
a detailed core examination including collec-
tion of medical history information, routine
physical examinations, laboratory tests, and
questionnaires. Dietary intake has been
assessed with a self-administered, semiquan-
titative food-frequency questionnaire
adapted from a well-validated questionnaire
used elsewhere (26).
Beginning in 1987, a 24-hr urine speci-
men was obtained at each subject’s regularly
scheduled examination. In addition, a blood
sample for lead analysis was collected at each
visit since 1988. Beginning in 1991, NAS
participants were recruited for a substudy of
K-X-ray ﬂuorescence (KXRF) bone lead mea-
surement. For the present study, we identi-
ﬁed 380 NAS participants who were subjects
in the KXRF bone lead substudy and who
had 24-hr urine specimens collected at two
consecutive visits that were judged to be valid
(i.e., had a volume of 750–2,900 mL and a
collection time of 20–28 hr). We retrieved
frozen urine aliquots from the first 24-hr
urine specimen, which coincided with the
participant’s initial (baseline) bone lead
determination and in which lead had previ-
ously been measured; thawed these aliquots
and measured their NTx content; and exam-
ined bone resorption as a potential modiﬁer
of the relationships of bone lead and blood
lead to urinary lead, and the relationships of
bone lead to blood lead. 
All research performed in our study 
was approved by the Human Research
Committees of Brigham and Women’s
Hospital and the Department of Veterans
Affairs Outpatient Clinic in Boston. 
Blood lead. We obtained and analyzed
whole-blood samples for lead by graphite
furnace atomic absorption with Zeeman
background correction (ESA Laboratories,
Chelmsford, MA). Values below the mini-
mum detection limit of 1 µg/dL (n = 3, <
1%) were coded as 0. The instrument was
calibrated with National Institute of
Standards and Technology Standard
Reference Material (NIST SRM 955a, lead
in blood) after every 20 samples. Ten per-
cent of samples were run in duplicate; at
least 10% of the samples were controls and
10% were blanks. In tests on reference
samples from the Centers for Disease
Control and Prevention (Atlanta, GA), the
coefficient of variation (CV) ranged from
8% for concentrations from 10 to 30 µg/dL
to 1% for higher concentrations. In this
study, the CV was 5% for concentrations
below 10 µg/dL. Compared with a NIST
target of 5.7 µg/dL, 24 measurements by this
method gave a mean [standard deviation
(SD)] of 5.3 (1.2) µg/dL.
Bone lead. We measured bone lead in
each subject’s mid-tibia shaft and patella
with a KXRF instrument (ABIOMED, Inc.,
Danvers, MA). The tibia and patella have
been targeted for bone lead research because
they consist mainly of cortical and trabecular
bone, respectively. A technical description
and the validity speciﬁcations of the KXRF
instrument have been published elsewhere
(27,28). The instrument provides an unbi-
ased estimate of bone lead levels (normalized
for bone mineral content and expressed as
micrograms of lead per gram of bone min-
eral) and an estimate of the uncertainty asso-
ciated with each measurement. 
Urinary lead. The methods used for uri-
nary lead measurement in this study are
described in detail elsewhere (24). In brief,
collection of 24-hr urine began after the ﬁrst
void of the morning and continued through
the first void of the subsequent morning.
Urine samples were collected in the presence
of an antioxidant (sodium metabisulﬁte) and
6 M hydrochloric acid to achieve a pH
between 2 and 3. The samples were stored at
–20°C until assay; thawed, aliquoted, and
digested with nitric acid at room tempera-
ture; and analyzed by inductively coupled
plasma mass spectrometry (ICP-MS, Sciex
Elan 5000; Perkin Elmer, Norwalk, CT)
with isotope dilution (29). Before analysis,
the mass spectrometer setting and nebulizer
flow rate were optimized to give maximum
peak intensity for lead. Data were expressed as
the average of five replicate measurements.
Quality control and quality assurance proce-
dures included analyses of procedural blanks
to monitor contamination and of NIST SRM
2670e (toxic elements in urine) to monitor
the accuracy and recovery rates for each ana-
lytic batch. The lead concentration in the
procedural blanks was 0.03 ng/mL, with a
detection limit of 0.02 ng/mL. Recovery of
the quality control standards was between
95% and 105%, and the precision of the lead
determination was approximately 1%.
Creatinine. We used the Beckman
Creatinine Analyzer 2 (Beckman, Brea, CA)
to measure creatinine in serum and in
archived (frozen) 24-hr urine samples by
routine laboratory method (Jaffe method).
This method of analysis has intra-assay CVs
of 1.3% at 1.2 mg/dL for serum and 2.4%
at 17.7 mg/dL for urine, respectively, and
interassay CVs of 3.3% at 1.1 mg/dL for
serum and 3.1% at 17.6 mg/dL for urine,
respectively. 
Urinary N-telopeptide. We thawed and
analyzed aliquots of urine samples for NTx by
a commercially available competitive-inhibi-
tion enzyme-linked immunosorbent assay (22)
(Osteomark; Ostex International, Seattle,
WA). NTx concentrations were expressed as
nanomoles of bone collagen equivalents nor-
malized to creatinine (nM BCE/mM creati-
nine). The sensitivity of the assay was 20 nM
BCE. The intra-assay CVs were 8.9% at 406
nM BCE and 8.7% at 1,563 nM BCE; the
interassay CVs were 8.6% at 427 nM BCE
and 5.6% at 1,513 nM BCE. To assess the
reliability of urinary NTx, we measured NTx
in the second 24-hr urine specimens for a ran-
dom subset of 50 participants and the intra-
class correlation coefﬁcient of these repeated
measures of NTx (collected, on average, 3
years apart) was 0.87.
Statistical methods. To account for
interindividual variability of glomerular
Table 1. Characteristics of 333 middle-aged and elderly male participants in a study of the influence of
bone resorption on bone lead mobilization.
Urinary N-telopeptide (nM BCE/mM creatinine) tertiles
Total Low: < 34 Medium: 34– < 52 High: ≥ 52
(n = 333) (n = 115) (n = 106) (n = 112) p-Value
Variables Mean (SD) Mean (SD) Mean (SD) Mean (SD) (ANOVA)
Age (years) 66.4 (6.3) 65.5 (3.7) 67.0 (6.08) 66.7 (6.7) NS
Body mass index (kg/m2) 27.7 (3.7) 28.5 (3.7) 27.7 (3.4) 27.0 (3.8)* 0.01
Urinary lead (µg/day)  5.7 (3.3) 5.7 (3.3) 5.5 (3.1) 6.0 (3.6) NS
Blood lead (µg/dL)a 6.1 (4.0) 5.8 (3.7) 5.9 (3.7) 6.6 (4.6) NS
Patella lead (µg/g) 31.1 (17.3) 31.0 (17.2) 32.8 (17.8) 29.7 (17.0) NS
Tibia lead (µg/g) 21.3 (12.2) 20.6 (11.4) 22.1 (12.0) 21.4 (13.2) NS
Serum creatinine (mg/mL) 1.2 (0.2) 1.2 (0.2) 1.2 (0.2) 1.2 (0.1) NS
Urinary creatinine (mg/dL) 96.9 (41.4) 94.8 (41.4) 96.8 (42.7) 99.2 (40.7) NS
Creatinine clearance rate (mL/min) 87.5 (29.3) 93.6 (33.6) 89.4 (27.6) 79.6 (21.0)*,** < 0.01
Urinary N-telopeptide (nM BCE) 417.8 (324.1) 219.4 (106.0) 354.1 (165.7)* 681.8 (402.2)*,** < 0.01
Urinary N-telopeptide  48.9 (33.8) 26.2 (5.5) 41.2 (4.9)* 79.5 (42.7)*,** < 0.01
(nM BCE/mM creatinine)
Abbreviations: BCE, bone collagen equivalent (equivalent moles of bone type I collagen from which the antigen is
derived); NS, not signiﬁcant (p > 0.05).
aThree subjects (< 1%) who had blood lead under detection limit of 1 µg/dL were coded as “0.” *Statistically signiﬁcantly
different from low NTx tertile. **Statistically signiﬁcantly different from medium NTx tertile. function, we adjusted urinary lead levels for
creatinine clearance rate (CCr), an estimate
of glomerular flow rate calculated from the
clearance rate of endogenously produced
creatinine. We calculated CCr (millimeters
per minute) as total amount of urine creati-
nine over 24 hr: milligrams/[serum creati-
nine concentration (milligrams/milliliter) ×
collection time (minutes)]. We calculated
the creatinine clearance-adjusted urinary
lead for each individual by taking the resid-
ual from the regression model in which cre-
atinine clearance was the independent
variable, plus a constant equal to the
expected urinary lead for the mean creati-
nine clearance of the study population.
Because urinary lead levels were skewed
toward the upper end, the regression model
to calculate creatinine clearance-adjusted
urinary lead was performed in the loge scale
to improve stability over the whole range of
urinary lead levels. 
We calculated descriptive statistics of
subjects’ characteristics by NTx tertiles (low:
< 34; medium: 34– < 52; high: ≥ 52
nMBCE/mM creatinine) and analysis of
variance (ANOVA). To assess the inﬂuence
of bone resorption on the release of lead
from bone, we ﬁrst regressed bone and blood
lead levels on urinary lead with interactions
of NTx tertiles and bone lead and blood
lead, and then stratified them by NTx ter-
tiles. Age, body mass index, cumulative ciga-
rette smoking (pack-years), and alcohol
consumption (grams per day) were included
in all regression models as potential con-
founders. We applied similar approaches to
assess the influence of bone resorption on
the relationship between bone lead and
blood lead. To examine the impact of factors
believed to affect lead kinetics in adults, we
also included vitamin C intake (30,31) and
calcium intake (32) in all regression models.
All nutrients examined were adjusted for
total energy intake to minimize extraneous
error (caused by individual differences in
total food intake) in estimating specific
nutrient intake and to reduce potential con-
founding by total food intake. We applied a
regression diagnostics procedure to the ﬁnal
model to identify potential outliers and
influential points. All analyses were per-
formed using SAS version 6.12 (SAS
Institute, Cary, NC).
Results
Among 380 eligible subjects, 26 with miss-
ing data on blood lead, patella lead, urinary
lead, CCr, or NTx, and 19 subjects with
reduced renal function (serum creatinine
concentrations of > 1.5 mg/dL) were
excluded. Two subjects were identified as
outliers by regression diagnostics because of
their low urinary lead levels (< 0.47 µg/day;
population mean ± SD was 5.7 ± 3.3
µg/day) and moderate to high blood lead
levels (≥ 14 µg/dL; population mean ± SD
was 6.1 ± 4.0 µg/dL) and bone lead levels
(patella lead levels ≥ 46 µg/g; population
mean ± SD was 31.1 ± 17.3 µg/g) and mod-
erate to high NTx levels (NTx = 50 and 193
nMBCE/mM creatinine; population mean ±
SD was 48.9 ± 33.8 nM BCE/mM creati-
nine). Thus, 47 subjects were excluded from
this analysis. Most (97%) of the remaining
333 subjects were white, and their character-
istics are summarized in Table 1. 
The mean of NTx in this group of mid-
dle-aged and elderly men was 48.9 nM
BCE/mM creatinine (Table 1). There was
no significant difference in blood, bone, or
urinary lead levels across tertiles of NTx by
ANOVA. As expected, lead measures in
blood and bone were moderately correlated
with CCr adjusted urinary lead (r = 0.3–0.6,
all p < 0.01; Table 2). NTx was marginally
associated with adjusted urinary lead (r =
0.10, p =0.07). 
Patella lead and tibia lead had stronger
associations with urinary lead in the upper
two NTx tertiles than in the lowest NTx ter-
tile (Tables 3 and 4). For example, after
adjusting for age and creatinine clearance, the
relation of patella lead to urinary lead was
approximately two times greater in the
medium and high NTx tertiles tertile (β =
0.017 and 0.015) than in the low NTx tertile
(β = 0.008; Table 4). We observed similar
results with regard to the relation of tibia lead
to urinary lead. However, we observed a
potentially significant modifying effect of
NTx only on the relationship between patella
lead and urinary lead (Table 3; overall p-
value for interactions = 0.06). We found no
statistically significant influence of NTx on
the relationship of blood lead to urinary lead. 
As expected, the magnitude of the rela-
tionship of bone lead to urinary lead dimin-
ished after adjustment for blood lead (Table
4). Nevertheless, the pattern of the relation-
ships of patella lead and tibia lead to urinary
lead across NTx tertiles remained unchanged.
Furthermore, the relation of patella lead to
urinary lead was approximately three times
greater in the medium and high NTx tertiles
(β = 0.010 and 0.009) than in low NTx ter-
tile (β = 0.003). None of the other variables
(body mass index, alcohol consumption,
cumulative cigarette smoking, dietary intake of
vitamin C and calcium) predicted urinary lead
level, nor did the inclusion of these variables
in the models change the regression coeffi-
cients of bone or blood lead levels to a
notable extent.
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Table 2. Pearson correlation of biologic markers of lead dose with age and urinary N-telopeptide (n =
333).
Variables Age loge(N-telopeptides) loge(urinary lead)a Blood lead Patella lead
loge(N-telopeptides) 0.07
loge(urinary lead)a 0.01 0.10
Blood lead 0.04 0.04 0.55*
Patella lead 0.31* –0.03 0.39* 0.43*
Tibia lead 0.35* 0.01 0.27* 0.34* 0.71*
a24-hr urinary lead was loge transformed and adjusted for creatinine clearance. *p ≤ 0.01.
Table 3. Multiple regression analysis of 24-hr urinary lead levels on blood or bone lead and adjusted for
age, urinary N-telopeptide tertiles, and the interaction between each lead measure and NTx tertile (n =
333).a
β (SE)
Independent variables Model I Model II Model III
Age (years) –0.001 (0.004) –0.011 (0.004)** –0.010 (0.005)*
Lead biomarkers
Blood lead (µg/dL) 0.077 (0.011)** — —
Patella lead (µg/g) — 0.008 (0.003)** —
Tibia lead (µg/g) — — 0.011 (0.004)**
Urinary N-telopeptide tertiles (nM BCE/mM creatinine)
T1 (low: < 34) 0.00 0.00 0.00
T2 (middle: 34– < 52) –0.006 (0.058) –0.016 (0.063) –0.012 (0.065)
T3 (high: ≥ 52) 0.050 (0.057) 0.133 (0.062)* 0.104 (0.064)
Interactions
Blood lead × T1 0.00 — —
Blood lead × T2 0.006 (0.016) — —
Blood lead × T3 –0.021 (0.014) — —
Patella lead × T1 — 0.00 —
Patella lead × T2 — 0.008 (0.004)* —
Patella lead × T3 — 0.006 (0.004) —
Tibia lead × T1 — — 0.00
Tibia lead × T2 — — 0.008 (0.006)
Tibia lead × T3 — — 0.005 (0.005)
a24-hr urinary lead was loge transformed and adjusted for creatinine clearance. *p ≤ 0.05; **p ≤ 0.01.Table 5 shows the results of regression
analyses of bone lead on blood lead in rela-
tion to NTx tertile. Similar to the ﬁndings of
the urinary lead analysis, the association
between patella lead and blood lead was
again higher in men in the upper two NTx
tertiles than in men in the lowest NTx ter-
tile, but this interaction was signiﬁcant only
for the highest compared with the lowest
NTx tertile (p = 0.045, data not shown). We
observed no increase in the relationship of
tibia lead to blood lead across NTx tertiles.
Inclusion of other covariates (alcohol con-
sumption, dietary intake of vitamin C and
calcium) in the models did not substantially
change the regression coefficients for bone
lead levels.
Discussion
To the best of our knowledge, this is the ﬁrst
study to assess the inﬂuence of bone resorp-
tion on the release of lead from bone using a
biomarker of bone resorption. We observed
a positive relation of blood lead and bone
lead to urinary lead after adjustment for
CCr. As reported previously, although blood
lead was a consistently important determi-
nant of urinary lead in the study population,
bone lead was shown to contribute indepen-
dently to urinary lead (24). Moreover, the
current analysis expands on this previous
observation by suggesting that the indepen-
dent contribution of bone lead to urinary
lead was higher among subjects with greater
bone resorption, although the association
was significant for patella but not for tibia
lead measures (Table 4). Some kinetic mod-
els as well as empirical observations have
suggested the possibility of an independent
contribution of bone lead to plasma lead
(33,34). Bone lead was a better biomarker of
lead dose than blood lead in recent studies of
the relationship of low-level lead exposure to
hypertension in men (2) and in women (3),
cognitive decrements (4,5), and low birth
weight (6). These findings raise concerns
that blood lead levels not only inadequately
represent levels of lead accumulated in bone
but also inadequately represent levels of lead
in plasma (the primary source of bioavailable
lead to most body organs), because bone
lead stores may inﬂuence plasma lead levels
independently of blood lead. Our findings
support these concerns.
The most likely explanation for our fail-
ure to ﬁnd a signiﬁcant modifying effect of
NTx on the tibia lead–urinary lead or tibia
lead–blood lead relationships is that as cortical
bone, the tibia is less prone to bone turnover
than the patella, which is trabecular bone.
Trabecular bone has greater metabolic activity
than cortical bone. Accordingly, lead stored in
trabecular bone has shown a stronger associa-
tion with circulating lead both in studies
using standard metabolic methods (35–37)
and in those using KXRF (12,38–40).
Furthermore, a recent study reported that
bone lead (particularly patella lead) exerts an
additional independent inﬂuence on plasma
lead after adjusting for whole blood lead in
individuals with no history of occupational
lead exposure (41). Our ﬁndings support the
argument that lead in trabecular bone is more
available for mobilization and has more inﬂu-
ence on the amount of lead excreted in urine
than cortical bone. 
Bone loss occurs with aging in both men
and women at a reported rate of 5–10% per
decade (42). Data on NTx in middle-aged
and elderly men are limited. Although data
on 24-hr NTx excretion are likewise sparse,
NTx levels in a previous study where 24-hr
values were available (43) were substantially
lower in men (n = 57, mean ± SD = 30.5 ±
20.4 nM BCE/mM creatinine) than in post-
menopausal women (n = 69, mean ± SD =
43.3 ± 27.7 nM BCE/mM creatinine). A
similar gender difference was reported in a
study where NTx was measured in morning
urine from the elderly (n = 374, mean = 30.0
nM BCE/mM creatinine for men; n = 364,
mean = 45.7 nM BCE/mM creatinine for
postmenopausal women not using estrogen)
(44). Although the current study was
restricted to male participants (n = 333,
mean ± SD = 48.9 ± 33.8 nM BCE/mM
creatinine), given similar or greater bone
resorption among postmenopausal women,
our results support a potentially important
role of bone resorption as a modiﬁer of lead
distribution and its resultant toxicity in both
men and women.
Our study was limited by its cross-sec-
tional nature, which made it impossible to
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Table 4. Multiple regression analysis of 24-hr urine lead levels on bone lead and blood lead by urinary
N-telopeptide (NTx) tertiles (n = 333).a
Urinary N-telopeptide (nM BCE/mM creatinine) tertiles
Low: < 34 Medium: 34 – <52 High: ≥ 52 
Independent variables (n = 115) (n = 106) (n = 112)
Model IV-I
Age –0.009 –0.016* –0.010
(0.008) (0.007) (0.008)
Patella lead 0.008** 0.017** 0.015**
(0.003) (0.002) (0.003)
Blood lead — — —
Model IV-II
Age –0.004 –0.010 –0.009
(0.006) (0.006) (0.007)
Patella lead 0.003 0.010** 0.009**
(0.002) (0.003) (0.003)
Blood lead 0.073** 0.058** 0.041**
(0.011) (0.011) (0.011)
Model V-I
Age –0.007 –0.010 –0.014
(0.008) (0.007) (0.008)
Tibia lead 0.010** 0.019** 0.017**
(0.004) (0.004) (0.004)
Blood lead — — —
Model V-II
Age –0.002 –0.005 –0.012
(0.006) (0.006) (0.008)
Tibia lead 0.001 0.009** 0.011**
(0.004) (0.003) (0.004)
Blood lead 0.076** 0.072** 0.047**
(0.011) (0.011) (0.011)
Values shown are regression coefﬁcients (β) and SEs (in parentheses).
a24-hr urinary lead was loge transformed and adjusted for creatinine clearance. *p ≤ 0.05; **p ≤ 0.01.
Table 5. Multiple regression analysis of blood lead on age and bone lead by urinary N-telopeptide (NTx)
tertiles (n = 333).
Urinary N-telopeptide (nM BCE/mM creatinine) tertiles
Low: < 34 Medium: 34 – < 52 High: ≥ 52 
Independent variables (n = 115) (n = 106) (n = 112)
Model VI
Age –0.069 (0.055) –0.113 (0.052)* –0.038 (0.062)
Patella lead 0.072 (0.020)** 0.130 (0.018)** 0.125 (0.024)**
Model VII
Age –0.070 (0.054) –0.063 (0.057) –0.044 (0.070)
Tibia lead 0.116 (0.029)** 0.138 (0.029)** 0.116 (0.035)**
Values shown are regression coefﬁcients (β) and SEs (in parentheses). 
*p ≤ 0.05; **p ≤ 0.01.delineate temporal relationships among fac-
tors. Renal function may inﬂuence the excre-
tion of NTx and lead because both are
excreted through glomerular filtration. To
minimize the effect of renal function, we
excluded all subjects with renal impairment
(serum creatinine levels > 1.5 mg/dL) and
adjusted urinary lead for creatinine clearance,
an estimate of glomerular ﬁltration function.
Furthermore, we repeated the analyses with
new NTx tertiles defined by NTx values
before creatinine correction, and the stratiﬁed
regression results were similar to those
reported in Tables 4 and 5, but the interac-
tion between patella lead and NTx (Table 3)
was no longer signiﬁcant. Thus, it is unlikely
that our findings were significantly influ-
enced by variability in renal function.
Lead in diet, in addition to bone lead
and blood lead, may contribute substantially
to lead in urine for individuals without occu-
pational exposure. Our study was further
limited by the fact that we did not measure
dietary intake of lead and were unable to dis-
tinguish between lead from the skeleton and
lead from dietary sources. Nevertheless, in
an aging population such as the NAS, with
moderate to high bone lead levels, the rela-
tive contribution of recent diet to urinary
lead excretion is likely to be minimal.
In summary, our ﬁndings are consistent
with the hypotheses that bone resorption
modiﬁes the release of lead from bone; that
bone, independent of blood, is a source of
lead in plasma among middle-aged and
elderly men because lead excreted in urine is
presumed to be derived from plasma; and
that whole-blood lead levels do not directly
predict plasma lead levels. Our ﬁndings also
indicate that urinary NTx levels can be used
in epidemiologic studies to measure the
potential modifying influence of bone
resorption on the risk of toxicity as assessed
by KXRF-measured bone lead levels.
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